NCT04282070 is a Phase 1 clinical trial of SHR-1701 in Nasopharyngeal Carcinoma, sponsored by Jiangsu HengRui Medicine Co., Ltd..

Who is sponsoring NCT04282070?

NCT04282070 is sponsored by Jiangsu HengRui Medicine Co., Ltd..

What drugs are being tested in NCT04282070?

Interventions in NCT04282070: SHR-1701, Gemcitabine, Cisplatin, Albumin Paclitaxel.

What condition does NCT04282070 study?

NCT04282070 studies Nasopharyngeal Carcinoma.

Is NCT04282070 still recruiting?

NCT04282070 is currently status unknown. Last updated 21 December 2021.

Last reviewed 2021-12-21 · How we verify

NCT04282070

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Status unknown Phase 1 Last updated 21 December 2021

What this trial tests

Phase 1 trial testing SHR-1701 in Nasopharyngeal Carcinoma in 91 participants. Status unknown.

Timeline

27 March 2020

Primary endpoint
16 April 2022

15 December 2022

Quick facts

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	91
Start date	27 March 2020
Primary completion	16 April 2022
Estimated completion	15 December 2022
Sites	1 location across China

Drugs / interventions tested

SHR-1701 — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Albumin Paclitaxel — full drug profile →

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open label, phase Ib Study of SHR-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of SHR-1701

Trials testing the same drug.

NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07517653 — Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma · Phase 2 · not yet recruiting
NCT07384234 — SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis · Phase 2 · not yet recruiting
NCT07355010 — A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant T · Phase 2 · not yet recruiting
NCT07147088 — Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. · Phase 2 · not yet recruiting

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other Jiangsu HengRui Medicine Co., Ltd. trials

Trials by the same sponsor.

NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04282070 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
Last refreshed: 21 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04282070.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing